GW Pharmaceuticals PLC GWPH:NASDAQ

Last Price$109.00NASDAQ Closing Price as of 4:00PM ET 8/12/20

Today's Change-0.80(0.73%)
Bid (Size)$109.00 (2)
Ask (Size)$111.00 (4)
Day Low / High$108.00 - 112.00
Volume523.4 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 08/12/2020

 

GW Pharmaceuticals PLC ( NASDAQ )

Price: $109.00
Change: -0.80 (0.73%)
Volume: 523.4 K
4:00PM ET 8/12/2020
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

Insider Trends: Insider at GW Pharmaceuticals Exercises Options Derivative Securities, Sells for Taxes and Self, Selling Trend Unaffected
8:08PM ET 8/12/2020 MT Newswires

On Aug 10, 2020, Chief Legal Officer, Douglas B Snyder, exercised options/derivative securities for 131,544 shares. A portion of these optioned shares...

2020 Estimate for GW Pharmaceuticals Increased but Q3, and 2021 Targets Decreased
7:10AM ET 8/11/2020 MT Newswires

GW Pharmaceuticals Plc's (NASDAQ:GWPH, Recent Price: 113.95) earnings forecasts for Q3 ending September 30, 2020, and the forecasts for 2020 and 2021 have...

European ADRs Move Lower in Friday Trading
11:03AM ET 8/07/2020 MT Newswires

American depositary receipts of European stocks were trading 0.84% lower at 921.93 on the BNY Mellon Europe Select ADR Index on Friday. In continental...

GW Pharmaceuticals Swings to Q2 Loss, Revenue Rises Year-on-Year
4:08PM ET 8/06/2020 MT Newswires

GW Pharmaceuticals (GWPH) swung to a Q2 net loss of $0.02 a share from profit a year earlier of $0.21, but that was narrower than the consensus on Capital...

Company Profile

Business DescriptionGW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. View company web site for more details
AddressSovereign House
Cambridge, Cambridgeshire CB24 9BZ
Phone+44.1223.266800
Number of Employees801
Recent SEC Filing08/12/20204
Chief Executive Officer & Executive DirectorJustin D. Gover
Chief Operating OfficerChristopher John Tovey
CFO & Principal Accounting OfficerScott M. Giacobello
Chief Medical OfficerVolker Knappertz

Company Highlights

Price Open$111.71
Previous Close$109.80
52 Week Range$67.98 - 166.59
Market Capitalization$3.4 B
Shares Outstanding31.1 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement11/03/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings116.47
Earnings per Share$1.01
Beta vs. S&P 500N/A
Revenue$15.5 M
Net Profit Margin8.24%
Return on Equity4.49%

Analyst Ratings as of 07/14/2020

Buy
15
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset